What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

mRNA Splicing: Mechanism, Regulation, and Errors

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to mRNA Splicing

What is mRNA Splicing?

Messenger RNA (mRNA) splicing is the post-transcriptional process by which non-coding intervening sequences, called introns, are removed from a precursor messenger RNA (pre-mRNA) transcript, and the remaining coding sequences, called exons, are covalently joined to form a mature mRNA. This process occurs in the nucleus of eukaryotic cells, typically co-transcriptionally—that is, while the pre-mRNA is still being synthesized by RNA polymerase II. The term "splicing" derives from the molecular action: the RNA backbone is cut at two defined phosphodiester bonds and the free ends are re-ligated, much like splicing a film reel.

The discovery of splicing in 1977 by Phillip Sharp and Richard Roberts, working independently on adenovirus transcripts, overturned the then-prevailing colinearity hypothesis—the assumption that genes and their RNA products were contiguous, unbroken sequences. We now know that the vast majority of human genes contain introns; the average human gene spans roughly 27,000 base pairs but its mature mRNA is only about 1,500 nucleotides, meaning that over 90% of the primary transcript is discarded during splicing.

Why Splicing is Essential

Splicing is essential for several reasons. First, it is a mandatory step in the expression of most eukaryotic protein-coding genes. An unspliced pre-mRNA cannot be exported to the cytoplasm, cannot be translated, and is typically degraded by the nuclear exosome or retained in the nucleus. Second, splicing provides an extraordinary mechanism for proteomic diversity through alternative splicing, whereby a single gene can produce multiple distinct mRNA isoforms by including or excluding different exons. It is estimated that over 95% of human multi-exon genes undergo alternative splicing, making it a primary driver of organismal complexity. Third, splicing is coupled to other aspects of mRNA Processing, including 5' capping and 3' polyadenylation, and it influences mRNA Stability through the deposition of exon-junction complexes that mark transcripts as properly processed.

The Chemistry of Splicing: Transesterification Reactions

Splicing is not an enzymatic hydrolysis that requires external energy in the form of ATP for the chemical bond rearrangements themselves. Instead, the chemistry relies on two sequential transesterification reactions—reactions in which one phosphodiester bond is broken and another is formed simultaneously, with no net gain or loss of atoms. The energy stored in the original phosphodiester bonds is conserved in the new bonds. ATP is consumed by the spliceosome, however, for the conformational rearrangements that position the reactive groups and for the proofreading of splice site selection.

Step 1: Branch Point Attack

The first transesterification reaction is initiated by a 2'-hydroxyl group on an adenosine residue located at the branch point, typically 18–40 nucleotides upstream of the 3' splice site. This adenosine's 2'-OH performs a nucleophilic attack on the phosphate at the 5' splice site—the phosphodiester bond between the last nucleotide of the exon and the first nucleotide of the intron. The result is cleavage of the 5' splice site and the formation of a new, unusual 2'–5' phosphodiester bond between the branch point adenosine and the 5' end of the intron. This creates a lariat intermediate: the intron is now looped back on itself in a lasso-like structure, and the 5' exon is free, ending in a 3'-hydroxyl group.

The branch point adenosine is not a special nucleotide by its chemistry alone; it is selected by its context within the branch point sequence and by its position relative to the splice sites. The 2'-OH of the branch point adenosine is normally involved in the sugar-phosphate backbone of the RNA, but it is available for this reaction because it is not engaged in a phosphodiester bond.

Step 2: Exon Ligation

In the second transesterification, the 3'-hydroxyl group of the detached 5' exon performs a nucleophilic attack on the phosphate at the 3' splice site—the phosphodiester bond between the last nucleotide of the intron and the first nucleotide of the 3' exon. This reaction cleaves the 3' splice site, releases the intron lariat (which is subsequently debranched by a specific RNA debranching enzyme and degraded), and joins the two exons together via a standard 3'–5' phosphodiester bond. The result is a mature mRNA with a contiguous open reading frame, ready for export and translation.

Both reactions are reversible in principle, but in vivo they are driven forward by the spliceosome's conformational changes and by the rapid degradation of the released lariat intron. The overall chemistry is summarized as follows:

Pre-mRNA: Exon 1—Intron—Exon 2
Step 1: Branch point 2'-OH attacks 5' splice site phosphate → Exon 1 (free 3'-OH) + Lariat intron—Exon 2
Step 2: Exon 1 3'-OH attacks 3' splice site phosphate → Exon 1—Exon 2 (ligated) + Lariat intron (released)

The Spliceosome: A Dynamic Ribonucleoprotein Machine

The spliceosome is a massive, dynamic ribonucleoprotein complex—approximately 60S in size, comparable to the ribosome—that catalyzes pre-mRNA splicing. It is composed of five small nuclear ribonucleoproteins (snRNPs), designated U1, U2, U4, U5, and U6, each containing a small nuclear RNA (snRNA) and a set of associated proteins. In addition to the snRNPs, the spliceosome contains numerous non-snRNP protein factors that participate in assembly, proofreading, and conformational rearrangements. The spliceosome is not a pre-assembled static machine; it assembles de novo on each intron in a stepwise, ATP-dependent pathway and disassembles after catalysis.

snRNPs and Their Functions

Each snRNP has a specific role in splice site recognition and catalysis:

U1 snRNP: Contains the U1 snRNA, which base-pairs with the 5' splice site consensus sequence. U1 is the first snRNP to recognize the pre-mRNA and is essential for defining the 5' boundary of the intron.
U2 snRNP: Contains the U2 snRNA, which base-pairs with the branch point sequence, bulging out the reactive adenosine so that its 2'-OH is positioned for the first transesterification.
U4/U6 snRNP: U4 and U6 snRNAs are extensively base-paired with each other in a di-snRNP complex. U6 is the catalytic core of the spliceosome; it coordinates the magnesium ions that catalyze both transesterification reactions. U4 acts as a chaperone, holding U6 in an inactive conformation until assembly is complete.
U5 snRNP: U5 snRNA interacts with exon sequences at both the 5' and 3' splice sites, aligning the two exons for the second transesterification and ensuring accurate ligation.

The catalytic heart of the spliceosome is U6 snRNA, which, together with U2 snRNA, forms a structure that resembles the active site of self-splicing group II introns. This has led to the widely accepted hypothesis that the spliceosome evolved from ancestral group II introns.

Spliceosome Assembly Pathway

Spliceosome assembly proceeds through a series of defined complexes, designated E, A, B, B*, and C. The process is ordered and ATP-dependent:

Complex E (Early/Commitment complex): U1 snRNP base-pairs with the 5' splice site, and the splicing factor U2AF (U2 auxiliary factor) binds the polypyrimidine tract and 3' splice site. SF1 (splicing factor 1) binds the branch point. This complex commits the intron to the splicing pathway.
Complex A (Pre-spliceosome): U2 snRNP joins, base-pairing with the branch point sequence in an ATP-dependent reaction. The branch point adenosine is bulged out.
Complex B: The U4/U6•U5 tri-snRNP joins the complex. U6 displaces U1 from the 5' splice site, and U4 is released.
Complex B* (Activated spliceosome): U4 is dissociated, and U6 undergoes a conformational rearrangement to form the catalytic core. This is the first catalytically competent complex.
Complex C: After the first transesterification, the spliceosome undergoes further rearrangements to form complex C, which catalyzes the second transesterification.
Disassembly: After exon ligation, the spliceosome dissociates, releasing the mature mRNA, the lariat intron, and the snRNPs, which are recycled for subsequent rounds of splicing.

This assembly pathway is conserved from yeast to humans, although the number of accessory proteins increases substantially in higher eukaryotes. For a deeper treatment of the molecular choreography, see Spliceosome Splicing.

Splice Site Recognition and Consensus Sequences

Splice sites are defined by short, degenerate consensus sequences that are recognized by the spliceosome. In humans, these sequences are not highly conserved individually, which allows for the flexibility required for alternative splicing but also means that splicing regulation is complex and easily perturbed by mutation.

5' Splice Site

The 5' splice site (also called the donor site) is located at the exon-intron boundary. The consensus sequence is:

5'—AG|GURAGU—3'

where the vertical bar indicates the cleavage site, R is a purine (A or G), and the intron begins with GU (almost invariant). The first two intronic nucleotides, GU, are essentially universal in nuclear pre-mRNA introns. U1 snRNA base-pairs with this sequence through complementary base pairing: the 5' end of U1 snRNA (3'-AUACUUACCUG-5') recognizes the 5' splice site. In higher eukaryotes, additional proteins, including U1-70K and U1C, stabilize this interaction.

Branch Point and Polypyrimidine Tract

The branch point sequence in mammals is loosely conserved as:

YNYURAC

where Y is a pyrimidine, N is any nucleotide, and the underlined A is the branch point adenosine that performs the nucleophilic attack. This sequence is located 18–40 nucleotides upstream of the 3' splice site. The branch point is recognized by U2 snRNA through base pairing, with the branch point adenosine bulged out of the duplex.

Immediately downstream of the branch point lies the polypyrimidine tract, a stretch of 10–20 pyrimidines (mostly uridines) that serves as a binding site for U2AF65, the large subunit of U2AF. The polypyrimidine tract is critical for recruiting U2 snRNP to the branch point and is a major determinant of 3' splice site strength. Longer, more pyrimidine-rich tracts generally correspond to stronger splice sites.

3' Splice Site

The 3' splice site (acceptor site) is located at the intron-exon boundary and is defined by:

YAG|G

The final two intronic nucleotides are AG (almost invariant), and the first nucleotide of the exon is typically G. The 3' splice site is recognized by U2AF35, the small subunit of U2AF, which binds the AG dinucleotide, and by U5 snRNP during the second catalytic step. The distance between the branch point and the 3' splice site is typically 18–40 nucleotides, and this spacing is important for correct positioning.

The degeneracy of these consensus sequences means that splice site "strength" is a continuum. Strong splice sites match the consensus closely and are recognized efficiently; weak splice sites deviate from consensus and require auxiliary splicing factors to be recognized. This variation underlies the regulation of alternative splicing.

Alternative Splicing: Generating Protein Diversity

Alternative splicing is the process by which different combinations of exons are included in the mature mRNA, allowing a single gene to produce multiple protein isoforms. This mechanism vastly expands the coding capacity of the genome and is particularly prevalent in vertebrates, where it contributes to the complexity of the nervous system, immune system, and other tissues.

Types of Alternative Splicing

There are five major modes of alternative splicing:

Exon skipping: An entire exon is excluded from the mature mRNA. This is the most common mode in humans.
Alternative 5' splice site selection: Two or more different 5' splice sites are used, leading to extension or truncation of the upstream exon.
Alternative 3' splice site selection: Two or more different 3' splice sites are used, leading to extension or truncation of the downstream exon.
Intron retention: An intron is retained in the mature mRNA. This is the most common mode in plants, fungi, and protozoa, but is relatively rare in mammals.
Mutually exclusive exons: Two or more exons are alternatively included such that only one is present in any given mRNA isoform.

A classic example is the DSCAM gene in Drosophila, which can theoretically generate over 38,000 distinct mRNA isoforms through combinations of alternative exons. In humans, the CD44 gene, involved in cell adhesion and cancer metastasis, produces numerous isoforms through alternative exon usage.

Regulatory Elements and Factors

Alternative splicing is regulated by the interaction of trans-acting protein factors with cis-acting RNA elements. These elements are classified by their location and effect:

Exonic Splicing Enhancers (ESEs): Sequences within exons that promote splicing by recruiting positive regulators.
Exonic Splicing Silencers (ESSs): Sequences within exons that inhibit splicing by recruiting negative regulators.
Intronic Splicing Enhancers (ISEs): Sequences within introns that promote splicing.
Intronic Splicing Silencers (ISSs): Sequences within introns that inhibit splicing.

The major families of splicing regulatory proteins are the SR proteins (serine/arginine-rich proteins) and the hnRNP proteins (heterogeneous nuclear ribonucleoproteins). SR proteins generally act as positive regulators: they bind ESEs and recruit U1 snRNP to weak 5' splice sites and U2AF to weak 3' splice sites, thereby promoting spliceosome assembly. hnRNP proteins generally act as negative regulators: they bind silencer elements and can multimerize along the RNA, blocking access of the spliceosome or looping out exons.

The balance between SR and hnRNP proteins, which varies by cell type, developmental stage, and in response to signaling, determines the outcome of splicing for any given transcript. This is the basis of tissue-specific and developmentally regulated alternative splicing. The regulation of splicing is also coupled to transcription: the rate of RNA polymerase II elongation influences whether weak splice sites are recognized, and splicing factors can be recruited by the C-terminal domain of RNA polymerase II.

Experimental Methods to Study Splicing

Several experimental approaches are used to analyze splicing patterns, quantify isoform abundance, and identify splicing regulatory elements.

RT-PCR and Gel Electrophoresis

Reverse transcription polymerase chain reaction (RT-PCR) is the most direct method for examining splicing. Total RNA is reverse-transcribed into cDNA using oligo(dT) primers or gene-specific primers, and the cDNA is then amplified by PCR using primers that flank the region of interest. The PCR products are resolved by agarose or polyacrylamide gel electrophoresis, and the sizes of the products reveal which exons are included.

A typical protocol: 1–2 µg of total RNA is reverse-transcribed using M-MLV reverse transcriptase at 42°C for 60 minutes. The resulting cDNA (1–2 µL) is used as template for PCR with Taq polymerase under standard conditions: initial denaturation at 95°C for 2 minutes, followed by 25–35 cycles of 95°C for 30 seconds, annealing at 55–60°C (depending on primer Tm) for 30 seconds, and extension at 72°C for 30–60 seconds (depending on amplicon length). Products are run on a 1.5–2% agarose gel containing ethidium bromide or a DNA-binding dye.

Quantitative RT-PCR (qRT-PCR) using isoform-specific primers or probes can measure the relative abundance of different splice isoforms. This approach is sensitive and can detect subtle shifts in splicing ratios.

High-Throughput RNA Sequencing

RNA sequencing (RNA-seq) has revolutionized splicing analysis by allowing genome-wide detection and quantification of splice isoforms. In a typical RNA-seq experiment, RNA is fragmented, converted to cDNA, ligated to adapters, and sequenced on a high-throughput platform (e.g., Illumina). The resulting short reads (typically 50–150 nucleotides) are aligned to the genome or transcriptome, and reads spanning exon-exon junctions are used to quantify isoform abundance.

The key metric for splicing analysis is the Percent Spliced In (PSI, Ψ) value, which represents the fraction of transcripts that include a particular exon or splice junction. PSI values range from 0 (exon always skipped) to 1 (exon always included). Differential splicing analysis between conditions (e.g., disease vs. normal) identifies exons whose inclusion changes significantly. Tools such as rMATS, MISO, and DEXSeq are commonly used for this purpose.

Minigene Splicing Assays

Minigene reporter assays are used to study the splicing of a specific region of interest in isolation. A genomic fragment containing the exon(s) and flanking intronic sequences of interest is cloned into an expression vector between two constitutive exons (often from a reporter gene such as β-globin or EGFP). The construct is transfected into cultured cells, and after 24–48 hours, RNA is harvested and analyzed by RT-PCR.

Minigene assays are particularly useful for testing the effects of mutations on splicing, for mapping regulatory elements, and for screening compounds that modulate splicing. They allow the researcher to control the sequence context and to test variants systematically.

Splicing Errors and Disease

Mutations that disrupt splicing are a major cause of human genetic disease. It is estimated that up to 15% of disease-causing point mutations affect splicing, and this is likely an underestimate because many mutations in exons are assumed to affect protein function when they actually disrupt splicing regulatory elements.

Examples of Splicing-Related Diseases

Spinal Muscular Atrophy (SMA) is a devastating neuromuscular disorder caused by loss of the SMN1 gene. Humans have a nearly identical paralog, SMN2, which differs by a single C-to-T transition in exon 7. This silent mutation disrupts an exonic splicing enhancer, causing exon 7 to be skipped in most SMN2 transcripts. The resulting protein is truncated and unstable. Because SMN2 cannot fully compensate for the loss of SMN1, patients develop motor neuron degeneration. The severity of SMA correlates inversely with SMN2 copy number. This disease is a paradigm for splicing therapy: the drug nusinersen (Spinraza) is an antisense oligonucleotide that blocks an intronic splicing silencer in SMN2 exon 7, promoting its inclusion and producing full-length SMN protein.

Cancer is frequently associated with aberrant splicing. Mutations in the splicing factor SF3B1 are common in myelodysplastic syndromes and chronic lymphocytic leukemia. These mutations alter the 3' splice site recognition of U2 snRNP, leading to widespread mis-splicing. Additionally, many oncogenes and tumor suppressors undergo altered alternative splicing in cancer. For example, the TP53 gene produces multiple isoforms with distinct activities, and the MDM4 gene undergoes alternative splicing that generates an oncogenic isoform lacking the p53-binding domain.

Duchenne Muscular Dystrophy (DMD) is caused by mutations in the DMD gene, which encodes dystrophin. Many mutations disrupt the reading frame, leading to a truncated, nonfunctional protein. Antisense oligonucleotide therapies (e.g., eteplirsen) are designed to induce exon skipping to restore the reading frame, producing a shorter but partially functional dystrophin protein.

Therapeutic Approaches Targeting Splicing

Several therapeutic strategies have been developed to correct or modulate splicing:

Antisense oligonucleotides (ASOs): Short, chemically modified nucleic acids that base-pair with pre-mRNA and sterically block splice sites or regulatory elements. They can promote exon skipping (as in DMD) or exon inclusion (as in SMA).
Small molecule splicing modulators: Compounds that bind splicing factors and alter their activity. For example, the compound risdiplam binds to the SMN2 pre-mRNA and promotes exon 7 inclusion.
Modified U1 snRNA: Engineered U1 snRNAs with altered specificity can be delivered to cells to redirect splicing to a desired site.
CRISPR-based approaches: Gene editing can correct splice site mutations or delete pathogenic exons.

These approaches are at various stages of clinical development, with nusinersen and risdiplam already approved for SMA.

Common Pitfalls and Misconceptions

Students frequently encounter several conceptual difficulties when learning about splicing. The following clarifications address the most common errors.

Splicing vs. RNA Editing

Splicing and RNA editing are distinct processes that are often confused. Splicing removes introns and joins exons; it changes the length of the RNA but does not alter the identity of the nucleotides that remain. RNA editing is the post-transcriptional modification of specific nucleotides within an RNA molecule, changing its sequence. Examples include cytidine-to-uridine (C-to-U) deamination by APOBEC enzymes and adenosine-to-inosine (A-to-I) deamination by ADAR enzymes. Inosine is read as guanosine by the translation machinery, so A-to-I editing can change codons and alter protein sequence. Splicing and RNA editing can both occur on the same transcript, but they are mechanistically unrelated.

Prokaryotes and Splicing

A common misconception is that splicing does not occur in prokaryotes. In fact, self-splicing introns (group I and group II introns) are found in bacteria, archaea, and bacteriophages. These introns catalyze their own excision without the need for a spliceosome. Group I introns use a guanosine cofactor for the first transesterification, while group II introns use an internal branch point adenosine, similar to nuclear pre-mRNA splicing. However, the vast majority of bacterial genes do not contain introns, and the spliceosome is absent from prokaryotes. So while splicing does occur in prokaryotes, it is rare and mechanistically distinct from the spliceosomal splicing of eukaryotic nuclear pre-mRNAs.

Intron vs. Exon Definitions

Students sometimes confuse introns and exons. Introns are non-coding sequences that are removed during splicing. Exons are sequences that are retained in the mature mRNA. However, the term "exon" does not mean "coding sequence" in the sense of protein-coding. Exons can include untranslated regions (UTRs) at the 5' and 3' ends of the mRNA. The 5' UTR is encoded by the first exon(s) upstream of the start codon, and the 3' UTR is encoded by the last exon(s) downstream of the stop codon. Furthermore, an exon can be conditionally included or excluded depending on alternative splicing, so the exon/intron annotation is context-dependent.

Another related misconception is that introns are "junk." While introns are not translated, they contain important regulatory elements, including splicing enhancers and silencers, and they can harbor non-coding RNAs, enhancers, and other functional elements. Introns also contribute to the evolution of new genes through exon shuffling.

Frequently Asked Questions

What is mRNA splicing?

mRNA splicing is the post-transcriptional process in eukaryotic cells by which introns (non-coding intervening sequences) are removed from a pre-mRNA transcript and exons (coding sequences) are joined together to form a mature mRNA. This process is catalyzed by the spliceosome, a large ribonucleoprotein complex, and is essential for the expression of most protein-coding genes.

What are the steps of mRNA splicing?

Splicing occurs in two transesterification reactions. In the first step, the 2'-hydroxyl group of a branch point adenosine attacks the phosphate at the 5' splice site, cleaving the RNA and forming a lariat intermediate. In the second step, the 3'-hydroxyl of the detached 5' exon attacks the phosphate at the 3' splice site, joining the exons and releasing the intron lariat. These reactions are catalyzed by the spliceosome and require ATP for conformational rearrangements.

Where does mRNA splicing occur?

Splicing occurs in the nucleus of eukaryotic cells, typically co-transcriptionally while the pre-mRNA is still being synthesized by RNA polymerase II. The mature mRNA is then exported to the cytoplasm for translation. Splicing does not occur in the cytoplasm, although cytoplasmic splicing has been reported in rare cases such as in platelets.

Why is mRNA splicing important?

Splicing is important for three main reasons. First, it is required for the expression of most eukaryotic genes, as unspliced pre-mRNA cannot be translated. Second, alternative splicing allows a single gene to produce multiple protein isoforms, vastly expanding the coding capacity of the genome. Third, splicing is coupled to other mRNA processing events and to mRNA Stability, ensuring that only properly processed transcripts are exported and translated.

What are common mRNA splicing issues?

Common splicing issues include mutations in splice sites or splicing regulatory elements that cause exon skipping, intron retention, or cryptic splice site usage. These errors can lead to truncated or aberrant proteins and are associated with many genetic diseases, including spinal muscular atrophy, cystic fibrosis, and various cancers. Splicing errors can also arise from mutations in splicing factors themselves.

What is the process of mRNA splicing?

The process of mRNA splicing involves the assembly of the spliceosome on the pre-mRNA. U1 snRNP binds the 5' splice site, U2 snRNP binds the branch point, and the U4/U6•U5 tri-snRNP joins to form the catalytically active complex. Two transesterification reactions then excise the intron and ligate the exons. The spliceosome disassembles, and the mature mRNA is released.

Does mRNA splicing occur in prokaryotes?

Splicing does occur in prokaryotes, but it is rare and mechanistically distinct from eukaryotic splicing. Bacteria and archaea contain self-splicing group I and group II introns that catalyze their own excision without a spliceosome. However, the vast majority of prokaryotic genes lack introns, and the spliceosome is absent from prokaryotes.

Key Takeaways

mRNA splicing removes introns and joins exons in pre-mRNA through two transesterification reactions, catalyzed by the spliceosome without net loss of chemical energy.
The spliceosome is a dynamic ribonucleoprotein machine composed of five snRNPs (U1, U2, U4/U6, U5) that assemble stepwise on each intron in an ATP-dependent manner.
Splice sites are defined by short, degenerate consensus sequences: the 5' splice site (AG|GURAGU), the branch point (YNYURAC), and the 3' splice site (YAG|G), with a polypyrimidine tract between the branch point and 3' splice site.
Alternative splicing is regulated by SR proteins and hnRNP proteins acting on exonic and intronic splicing enhancers and silencers, allowing one gene to produce multiple mRNA isoforms.
Splicing errors caused by mutations in splice sites or regulatory elements underlie numerous genetic diseases, including spinal muscular atrophy and many cancers.
Therapeutic strategies targeting splicing include antisense oligonucleotides, small molecule modulators, and modified U1 snRNAs, several of which are approved or in clinical trials.
Splicing is distinct from RNA editing, occurs in the nucleus co-transcriptionally, and is rare but present in prokaryotes via self-splicing introns.